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Summary Bryostatin 1, an anti-neoplastic agent and protein kinase C activator, has dose-limiting toxicity
manifesting as myalgia. Studies in vivo have suggested that this myalgia may be caused by impairment of
oxidative metabolism as mitochondrial capacity, muscle reoxygenation and proton washout from muscle are
reduced by bryostatin, possibly as a result of vasoconstriction. To investigate these mechanisms further, and to
enable use of bryostatin for prolonged periods, the effect of a vasodilator on the established effects of
bryostatin on calf metabolism was studied using 31p magnetic resonance spectroscopy and near infrared
spectroscopy. Six patients with disseminated melanoma were examined on four occasions: before and 1 week
after initiation of long-term nifedipine (10 mg twice daily) treatment and then 4 and 48 h after bryostatin
infusion (25 ,ug m-2). Nifedipine impaired muscle oxidative metabolism but had no effect on proton efflux or
muscle reoxygenation rate. In the presence of nifedipine, two of the effects of bryostatin, impaired
reoxygenation rate and reduced proton efflux, were abolished, but the impaired mitochondrial activity
remained. These results show that nifedipine counteracted the vasoconstrictive effect of bryostatin 1. However,
because nifedipine itself had an unexpected effect on mitochondrial metabolism, it was not possible to assess
whether nifedipine modified bryostatin's effect on this variable. There was no additive detrimental effect of
bryostatin on mitochondial metabolism and nifedipine did not reduce the clinical toxicity of bryostatin 1, which
cannot therefore be due to vasoconstriction.
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Bryostatin 1, a protein kinase C activator (Kraft et al., 1986),
is used as an anti-neoplastic agent. It has dose-limiting
toxicity manifesting as myalgia about 48 h after administra-
tion (Philip et al., 1993; Prendiville et al., 1993). The muscle
pain is generalised and frequently starts in the calf muscles.
The symptoms become increasingly severe and prolonged
with each course of bryostatin. The aetiology of this toxicity
is unknown. Investigations including analysis of plasma
creatine phosphokinase, urine myoglobin excretion and
electromyography have failed to show evidence of either
muscle inflammation or peripheral neuropathy. There is
recent evidence of vasoconstriction following treatment with
bryostatin ex vivo (K Clarke and P Hickman, personal
communication) and probably in vivo as well (Hickman et al.,
1995). Separate to, or because of, this vasoconstriction,
bryostatin has caused mitochondrial dysfunction and reduced
proton efflux from skeletal muscle during recovery from
exercise (Hickman et al., 1995).
In patients with disseminated malignant melanoma
scheduled to receive bryostatin, we have examined the effect
of pretreatment with a vasodilating agent, nifedipine, on
muscle oxidative and non-oxidative ATP synthesis, muscle
reoxygenation rate and on the occurrence and severity of
myalgia. Nifedipine is an L-type calcium channel blocker and
belongs to the dihydropyridine group of drugs that cause
smooth muscle relaxation and hence vasodilatation. Muscle
metabolism was examined using 31P magnetic resonance
spectroscopy (MRS), a non-invasive measure of muscle
aerobic and anaerobic metabolism, and muscle reoxygena-
tion rate was measured by near infrared spectroscopy
(NIRS), a non-invasive measure of muscle oxygen supply.
These studies were designed to define the extent to which
vasoconstriction is involved in the aetiology of the metabolic
changes and myalgia that follow bryostatin treatment and
whether the use of a vasodilator allows a greater duration of
bryostatin therapy to be tolerated by the patient.
Subjects and methods
Six physically active patients with malignant melanoma were
recruited from a Cancer Research Campaign phase I clinical
trial of bryostatin 1 in disseminated malignancies unrespon-
sive to conventional treatment. Clinical details are in Table I.
Patients received weekly 1 h infusions of bryostatin at a dose
of 25 jug m-2 for 3 weeks (course 1 -3), there was 1 week of
no bryostatin therapy and then they received three more
weekly infusions (courses 4-6). Before the first infusion,
subjects were examined by both 31P-MRS and NIRS on two
separate occasions. After the initial combined MRS and
NIRS studies, the subject was treated throughout the
Table I Clinical details of patients studied
Bryostatin courseb
Case Age Sex Myalgia gradea before onset ofmyalgia
1 61 F 3 3
2 53 F 2 2
3 67 M 2 1
4 60 F 2 1
5 64 F 1 4
6c 47 M - _
7 58 M 1 4
aMaximal myalgia experienced bypatient:'grade 0, no pain; grade 1,
mild pain not requiring analgesia; grade 2, moderately severe pain with
irregular analgesia; grade 3, moderate to severe pain requiring non-
opiate analgesia(Philip et al., 1993). bBryostatin chemotherapy was
occasionally continuedbeyond thiscoursedespite thepresence ofgrade
I myalgia.cMyalgia impossible to assess due to the development of
spinal nerve compression that prevented evaluation ofthe aetiology of
any muscle pain. Patient 7 did not receive nifedipine before bryostatin
infusion
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remainder of the six courses of bryostatin with slow release
nifedipine 10 mg twice daily. One week after commencement
of nifedipine, repeat MRS and NIRS studies were performed
and then the patient received the first infusion of bryostatin.
Four hours after this infusion the third pair of studies was
performed and the final studies were completed 48 h after the
infusion.
To define more precisely the effect of bryostatin on muscle
reoxygenation rate, five patients receiving bryostatin without
nifedipine were examined by NIRS [four of these patients
have been presented previously (Hickman et al., 1995)]. These
studies were performed before and 4 h after an infusion of
bryostatin at a dose of 25 Mg m-2. Informed consent was
obtained from all subjects and the project received the
approval of the local ethics committee.
Magnetic resonance spectroscopy
Subjects were placed in a whole-body 2 T magnet (Oxford
Instruments, Oxford, UK) interfaced to a Bruker spectro-
meter (Bruker, Coventry, UK). The right calf muscle was
positioned over a 6-cm-diameter surface coil. Data were
collected with an 80 Ms pulse width and a 2 s interpulse delay.
Two 64-scan spectra were acquired at rest. Patients then
exercised by plantar flexion at a rate of 30 min-1 lifting 10%
lean body mass [obtained from skinfold thickness using
standard tables (Durnin and Womersley, 1974)] for 5 min,
after which the weight was increased by 2% lean body mass
every 1.25 min until fatigue or rapid PCr depletion was
observed. Thirty-two scan spectra (1.25 min each) were
collected throughout exercise. During recovery, four eight-
scan spectra, four 16-scan, three 32-scan and two 64-scan
spectra were collected (13 min of recovery in total).
Signals were detected from inorganic phosphate (Pi),
phosphocreatine (PCr), adenosine triphosphate (ATP) and
phosphodiesters (PDEs), and were processed by exponential
multiplication and Fourier transformation. Signal intensities
were obtained by using a time domain-fitting programme
(VARPRO, designed by R de Beer, Utrecht, The Nether-
lands), which identifies a specified number of exponentially
decaying signals in the free induction decay acquired from the
muscle using prior knowledge of the expected amplitudes,
relative positions and widths of the peaks to be fitted.
Cytosolic concentrations of Pi and PCr (in mmol 11
intracellular water) were calculated from the relative signal
intensities of Pi, PCr and ATP corrected for differential
magnetic saturation and assuming an intracellular ATP
concentration in resting muscle of 8.2 mmol 1-1 intracellular
water (Arnold et al., 1984). Cytosolic pH was determined from
the chemical shift of Pi from PCr (Arnold et al., 1984). Free
[ADP] (pM) in the cytosol was calculated from pH and [PCr]
and the equilibrium constant of the creatine kinase reaction,
assuming a normal [total creatine] of 42.5 mM (Arnold et al.,
1984; Veech et al., 1979). During exercise, [PCr] was expressed
as PCr/(PCr+Pi), which corrects for signal loss as a result of
leg movement with respect to the coil.
Mitochondrial ATP synthesis was assessed from the
recovery kinetics of [PCr] after exercise as described elsewhere
(Kemp, 1994). The half-time of PCr recovery is sensitive to
abnormalities of mitochondrial metabolism (Arnold et al.,
1984) and was calculated from a semilogarithmic plot. To
analyse mitochondrial function in more detail we also
calculated the initial rate of PCr resynthesis (d[PCr]/dt) by
comparing [PCr] at the end of exercise and at the first data
point in recovery (t =0.13 min). This is a direct estimate ofthe
rate of mitochondrial ATP synthesis, which is driven by
cytosolic [ADP] according to a hyperbolic relationship (Kemp
et al., 1993a). To quantify mitochondrial function, this
relationship was used together with the measured initial PCr
recovery rate to calculate the apparent maximum rate of
oxidative ATP synthesis as
Qmax =(d[PCr]/dt){1+Km/[ADP]}
where Ki,m the [ADP] for half-maximum oxidative ATP
synthesis, is assumed to be 30 gM (Kemp et al., 1993a).
The recovery of pH after exercise depends on the proton
efflux from the muscle. This was quantified by using changes
in pH and [PCr] at the start of recovery to calculate the
initial rate ofproton efflux (Kemp and Radda, 1994; Kemp et
al., 1993b). Proton efflux rate is given by
(d[PCr]/dt)/[1 + Io(PH-6.75)]+fidpH/dt
where f,, the cytosolic buffer capacity, is taken as 20 slykes
plus the contribution of Pi. The calculation is performed for
the first two intervals of recovery (t=0-0.13 and 0.13-
0.47 min) and the results averaged (Kemp and Radda, 1994;
Kemp et al., 1993b).
Near infrared spectroscopy studies
Tissue reoxygenation rates were measured in the arm
muscles after exercise by NIRS of flexor digitorum
superficialis using a commercial apparatus (RunMan, NIM
Inc. Philadelphia, PA, USA). The near infrared light source
was placed over the muscle and reflected light was compared
at 760 and 850 nm to distinguish relative amounts of
oxygenated and deoxygenated haemoglobin. Exercise in-
volved finger flexion lifting a weight of 1.5 kg for about
1 min. A cuff was then inflated about the upper arm to
20 mmHg above systolic pressure and exercise continued for
another 20-30 s until apparent maximal deoxygenation of
the muscle was achieved. The cuff was deflated 5 s after the
cessation of exercise and the half-time of the subsequent
reoxygenation was measured.
Data analysis
Results are expressed as mean+s.e.m. Differences from basal
values were assessed by Student's paired t-test, a significant
difference was taken to be present when P<0.05.
Results
Three different end points of the effect of nifedipine on
bryostatin toxicity were evaluated, namely clinical evaluation,
31P MRS examination and NIRS examination of the patient.
Clinically, the pretreatment of patients with nifedipine did
not allow a greater number of bryostatin courses to be
administered (4.4+0.7 courses with nifedipine, 4.4+0.6
courses without nifedipine) (the latter data from 14 patients
published in Hickman et al., 1995; S Wilner, personal
communication), and a mean of 2.2+1.3 courses of
bryostatin were given before onset of myalgia. Nifedipine
had no beneficial effect on the severity or the time of onset of
myalgia (Table I).
Bioenergetically, there were no changes in pH or any
metabolite ratio in resting muscle following nifedipine or
combined bryostatin and nifedipine treatment (Table II).
Exercise duration, the concentrations of PCr, Pi, ATP and
ADP and the cytosolic pH at the end of exercise were
unchanged following treatment with nifedipine or with
nifedipine and bryostatin (Table II).
Nifedipine, itself, had an effect on the mitochondrial
oxidative capacity, Qmax, which was reduced following
commencement on nifedipine and did not significantly
change following subsequent bryostatin infusion (Figure 1).
Nifedipine had no independent effect on proton efflux, but
the previously reported reduced proton efflux following
bryostatin infusion (Hickman et al., 1995) was abolished by
pretreatment with nifedipine (Table II).
Assessment ofmuscle oxygen supply by NIRS showed that
muscle reoxygenation rate did not alter after nifedipine or
bryostatin/nifedipine treatment. This suggests that the blood
flow to the muscle did not alter following either drugtreatment. This should be contrasted with the results ofNIRS
of five patients who did not receive any nifedipine treatment
before bryostatin infusion where a significant increase in
muscle reoxygenation half-time was observed. Combining the
NIRS data from the published study ofHickman et al. (1995)
(four subjects) with data from one new subject in whom no
nifedipine was used, the mean reoxygenation half-time
following bryostatin infusion alone was 25+8 s, significantly
greater (P<0.05) than the prebryostatin control value of
14+4 s. This decrease in muscle reoxygenation rate following
exercise implies poor muscle blood flow, presumably as a
result of vasoconstriction.
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Figure 1 Changes in apparent mitochondrial capacity during
treatment with bryostatin and nifedipine. The figure shows
individual values of the apparent mitochondrial capacity (Qmax)
After the initial studies (study 1), subjects were started on slow
release nifedipine 10mg twice daily orally throughout the
remainder of the protocol. One week following commencement
of nifedipine, subjects were examined again (study 2), after which
the patient received an infusion ofbryostatin (25 Mg m-2). Studies
were then performed 4h (study 3) and 48h after this infusion
(study 4). Details of patients are in Table I. Mean values of these
data and statistical significance of the changes are given in Table
II.
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Discussion
In the absence of nifedipine, bryostatin caused a decrease in
proton efflux from the muscle and a decrease in mitochon-
drial function (Hickman et al., 1995). These changes could be
explained as resulting from bryostatin-induced vasoconstnc-
tion in vivo, as has been observed in the isolated perfused rat
heart (K Clarke and P Hickman, personal communication).
Combining the NIRS studies in one patient with those from
the four patients previously reported by Hickman et al.
(1995), we can demonstrate that bryostatin causes a
significant reduction in the reoxygenation rate (n =five
patients) (Table II). This suggests reduced muscle blood
flow could underlie the myalgia that is the dose-limiting
toxicity for bryostatin.
We studied the effect of treatment with nifedipine on
muscle reoxygenation rate and muscle ATP synthesis and the
effect of this prior treatment with nifedipine on the
occurrence and severity of bryostatin-induced myalgia and
on the bryostatin-induced changes in muscle perfusion and
metabolism. Nifedipine did not change muscle proton efflux
or reoxygenation rate but did reduce the oxidative ATP
synthesis rate (Table II). Four hours following bryostatin
infusion, both the reduction in reoxygenation rate and the
reduction in proton efflux reported by Hickman et al. (1995),
were absent with nifedipine pretreatment (Table II). This
suggests that bryostatin may have induced vasoconstriction
that was counteracted by nifedipine. Bryostatin did not
significantly change oxidative ATP synthesis beyond the level
induced by nifedipine. Nifedipine may have obscured an
adverse mitochondrial effect of bryostatin.
The pretreatment of patients with nifedipine did not
significantly affect the onset or the severity of myalgia caused
by bryostatin infusion (Table I). The bryostatin-induced
reduction in reoxygenation rate and proton efflux (both of
which relate to muscle perfusion) have been removed by
pretreatment with nifedipine, yet the myalgia was still
present. This lack of effect of nifedipine on the myalgia
suggests that this clinical manifestation of bryostatin toxicity
cannot be due to the vasoconstrictive effects of bryostatin. It
also suggested that, while the myalgia may have been related
to temporary mitochondrial dysfunction caused by bryosta-
tin, mitochondrial dysfunction per se did not cause myalgia
Table I 31P-MRS and NIRS of skeletal muscle before and after nifedipine and bryostatin treatment
Study I Study 2 Study 3 Study 4
Measurement and unit Pre-treatment Nifedipine Nifedipine 4 h post- Nifedipine 48 h post-
bryostatin bryostatin
31p magnetic resonance spectroscopy
Resting muscle
pH 7.03+0.00 7.01 + 0.04 7.02+0.01 7.01 +0.02
PCr/ATP 3.85±0.23 3.68+0.17 3.70±0.17 3.95±0.31
Pi/ATP 0.49±0.04 0.50 ±0.09 0.45 ±0.03 0.47+0.09
[ADP] (gM) 8±2 9±2 9+3 8+2
PDE/ATP 0.28 ±0.07 0.22±0.04 0.23+ 0.04 0.19 +0.04
Exercising muscle
Exercise duration (min) 5±1 6+ 1 6+ 1 6+ 1
End exercise
PCr/(PCr+Pi) 0.46+0.07 0.41 +0.06 0.41 ±0.06 0.39±0.04
pH 6.82+0.13 6.80+0.08 6.81 + 0.08 6.80+0.09
[ADP] (,M) 41±5 51+6 54+5 51±9
Recovering muscle
Initial proton efflux (mM mir-') 8+3 7+3 7+ 3 9+4
Initial PCr recovery rate (mM miri-) 17+1 16+2 15+ 1* 19+2
Qmax (mMmin-l) 32+3 25+3* 24+2* 32+3
t1PCr (s) 39+11 31+6 38+7 33+5
ti ADP (s) 15+0 11 +1 10+3 11+1
Near-infrared spectroscopy
t1 reoxygenation (s) 14+3 17+3 16±3 16±4 2
Results are shown (mean+s.e.m.) from four studies from each patient. After the initial studies (study 1), subjects were started on slow-release
nifedipine 10 mg twice daily orally throughout the remainder of the protocol. One week following commencement of nifedipine, subjects were
examinedagain (study2), afterwhich thepatient received aninfusion ofbryostatin (25 Mg m-2). Studieswere then performed 4 h (study 3) and48 h
after this infusion (study 4). Details ofpatients are in Table I. *Significantly different from study 1 (P<0.05 by paired t-test).
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or myalgia would have been a feature of the pretreatment
with nifedipine. Pretreatment with nifedipine did not allow an
increased dose of bryostatin to be administered. It is possible
that a vasodilator that does not inhibit mitochondrial
function may be of more use than nifedipine.
Oxidative ATP synthesis was reduced after treatment with
nifedipine before administration of bryostatin despite there
being no change in reoxygenation rate of the muscle
following exercise (Table II). This suggests that nifedipine
has a direct effect on mitochondrial function. It is possible
that this effect is brought about by nifedipine's influence on
intracellular calcium. Skeletal muscle contraction relies upon
a rapid increase in cytosolic calcium and most of the
necessary calcium is released from the sarcoplasmic
reticulum (Frank and Oz, 1992) and nifedipine has been
shown to reduce release of calcium by the sarcoplasmic
reticulum (Rios and Brum, 1987). A change in cytosolic
calcium levels during muscle exercise could affect intrami-
tochondrial concentrations of calcium (McCormack et al.,
1992) and potentially change oxidative enzyme activities such
as pyruvate dehydrogenase, a-ketoglutarate dehydrogenase
and succinate dehydrogenase (McCormack et al., 1992). In
isolated liver preparations, nifedipine reduced microsomal
oxygen consumption (Engineer and Sridhar, 1991) and
nicardipine, a related dihydropyridine, decreased intramito-
chondrial calcium (Tari et al., 1987). Nifedipine treatment of
healthy volunteers caused a significant reduction in maximal
oxygen consumption and performance time on a cycle
ergometer without an alteration in maximal heart rate or
pulmonary ventilation (Gordon et al., 1986). It is possible
that the reduced mitochondrial capacity caused by nifedipine
could have been on the basis of alterations in the calcium
fluxes from extracellular or intracellular locations during
exercise. Whatever the mechanism, if nifedipine induced a
decrease in intramitochondrial calcium, oxidative enzyme
activation in vivo would fall and produce the reduced Qmax
demonstrated by 31P MRS following nifedipine treatment.
Bryostatin infusion following nifedipine did not lower
mitochondrial capacity further (Table II). Bryostatin 1 is a
potent activator of protein kinase C (Kraft et al., 1986), as
are the phorbol esters (Prendiville et al., 1993). Phorbol ester-
induced activation of protein kinase C has been reported to
affect intracellular calcium, although both elevation and
reduction in cytosolic calcium have been reported (Dosemeci
et al., 1988; Tseng and Boyden, 1991; Lacerda et al., 1988).
Since mitochondrial function can be influenced by local
changes in calcium concentration, an alteration in cytosolic
and mitochondrial calcium handling might have caused the
bryostatin-induced reduction in Q..ax seen by Hickman et al.
(1995).
In summary, bryostatin caused a significant delay in the
muscle reoxygenation rate 4 h after infusion, probably on the
basis of vasoconstriction. The daily administration of
nifedipine for a week before the bryostatin infusion removed
this reduction in reoxygenation half-time and also prevented
the reduction in proton efflux induced by bryostatin therapy
alone. This implied that nifedipine could prevent vasocon-
striction normally caused following the bryostatin infusion.
There was a reduction in the calculated maximal oxidative
ATP synthesis rate of skeletal muscle following administra-
tion of nifedipine. This may have been due to a direct effect
on the mitochondria by the calcium channel blocker or an
indirect effect on calcium fluxes within the muscle cell.
Bryostatin infusion combined with nifedipine administration
had no further detrimental effect on mitochondrial function.
The use of nifedipine had no effect on the occurrence or
severity of myalgia after bryostatin infusion, suggesting that
the aetiology of the myalgia was unrelated to muscle
perfusion or to mitochondrial dysfunction per se (at least
the type of mitochondrial dysfunction caused by nifedipine).
The mechanism of bryostatin-induced myalgia, its dose-
limiting toxicity, remains unknown. Studies with a vasodi-
lator that does not induce mitochondrial dysfunction should
still be evaluated as different mechanisms of mitochondrial
dysfunction may have different effects on muscle pain.
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